Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.72 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.52 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | RXRB | P28702 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL377242 | 0.98 | ACHE (0.70) | ACHECYP26A1CYP26B1HDAC8NR1H4 | |
| SCHEMBL16775747 | 0.86 | ACHE (0.68) | ACHECYP26A1CYP26B1HDAC8NR1H4 | |
| SCHEMBL6581884 | 0.85 | ACHE (0.72) | ACHECYP26A1CYP26B1HDAC8NR1H4 | |
| SCHEMBL21156766 | 0.84 | ACHE (0.53) | ACHECYP26A1CYP26B1HDAC8HDAC2 | |
| SCHEMBL11749643 | 0.84 | ACHE (0.70) | ACHECYP26A1CYP26B1HDAC8NR1H4 | |
| SCHEMBL30479628 | 0.84 | ACHE (0.70) | ACHECYP26A1CYP26B1HDAC8NR1H4 | |
| SCHEMBL716488 | 0.84 | CES2 (0.65) | ACHEHDAC2MEN1KMT2AHDAC3 | |
| SCHEMBL10389972 | 0.82 | SMN1; SMN2 (0.54) | ACHESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL27857311 | 0.80 | ACHE (0.46) | ACHEHDAC8HDAC6RXRARXRB | |
| SCHEMBL11630586 | 0.80 | ACHE (0.55) | ACHECYP26A1CYP26B1HDAC8NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20110263591-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER SCHERING PHARMA AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263591-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER SCHERING PHARMA AG (DE) | 2011-10-27 | — | — | US | disclosed |
| CN-101203482-B | Process for producing optically active aminoalkylphenols | BASF AG | 2011-07-13 | — | — | CN | disclosed |
| US-7977485-B2 | 2-heteroaryl carboxamides | BAYER SCHERING PHARMA AKTIENGESELLSHAFT (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20090143412-A1 | FUROPYRIDINE AND FUROPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER HEALTHCARE LLC (US) | 2009-06-04 | — | — | US | disclosed |
| US-7429584-B2 | Furo[2.3-b]pyridine derivatives for the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-30 | — | — | US | disclosed |
| CN-101203482-A | Process for producing optically active aminoalkylphenols | BASF AG (DE) | 2008-06-18 | — | — | CN | disclosed |
| US-6624188-B1 | Administered to treat or prevent one or more of the diseases and conditions selected from the group consisting of dermatoses, atherosclerosis and restenosis resulting from neointimal hyperproliferation, non-malignant and | ALLERGAN, INC. | 2003-09-23 | — | — | US | disclosed |
| US-5324840-A | Skin disorders | ALLERGAN, INC. (US) | 1994-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | ACHE 3695/4885CYP26A1 3566/4885CYP26B1 2750/4885 |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | ACHE 486/4885CYP26A1 4295/4885CYP26B1 4168/4885 |
| US-20090143412-A1 | FUROPYRIDINE AND FUROPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | NCOR1, NR3C1, NR3C2 | ACHE 4872/4885CYP26A1 207/4885CYP26B1 188/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | ACHE 33/4885CYP26A1 1148/4885CYP26B1 1565/4885 |
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ACHE 1463/4885CYP26A1 4165/4885CYP26B1 3841/4885 |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNA3 | ACHE 971/4885CYP26A1 2393/4885CYP26B1 2814/4885 |
| US-20110263591-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | ACHE 56/4885CYP26A1 2361/4885CYP26B1 2885/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | ACHE 33/4885CYP26A1 1148/4885CYP26B1 1565/4885 |
| US-11827662-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | ACHE 3695/4885CYP26A1 3566/4885CYP26B1 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.